{"name":"Ascletis Pharma (China) Co., Limited","slug":"ascletis-pharma-china-co-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ASC30 tablets","genericName":"ASC30 tablets","slug":"asc30-tablets","indication":"Other","status":"phase_2"},{"name":"ASC30","genericName":"ASC30","slug":"asc30","indication":"Other","status":"phase_1"},{"name":"ASC47","genericName":"ASC47","slug":"asc47","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ASC30 tablets","genericName":"ASC30 tablets","slug":"asc30-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC30","genericName":"ASC30","slug":"asc30","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC47","genericName":"ASC47","slug":"asc47","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPdU1KMGl6UHZndmd2cjlmdWZ1UnlGaFVYMzdDUnZWV3AyRzlDb1pabUVxX2NWcDJWN3RaUXEwQ0ptRlNXa2VfbWNOY3d1dkNxZV9rd0pkdUQzSmpuRXdyYTl6dWZGTjIzTFhMc3F4dlRrS0pNTloxbjFiWEQ5eXVVSmZB?oc=5","date":"2026-04-07","type":"pipeline","source":"AASTOCKS.com","summary":"Ascletis Pharma-B (01672.HK) Selects ASC30_39 FDC for Clinical Development - AASTOCKS.com","headline":"Ascletis Pharma-B (01672.HK) Selects ASC30_39 FDC for Clinical Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxNZzVjcEZsYXJtM1NMSmJRM0JGVUh5d2d1TWI5aHk2TVJMUGtCLU1DZ3ZMWmV1N2RWdUVJVUhJa0lxMXpiWGhmMTRaWXBWbkw5WGpOeFBBa19WcldyN3ZpeDlwanJNVURQVkVrOE9wLWN4WndwM1J6MmlycHJxYkhPMDZIQkN3bkpIMnR6NG1RaW9rY2d1ODE0bWJUelBncEhqNUtPY0VxenpRaVdBeWJlXzY2eF9GSkMwTGZwUGtMa1lnQ1VRQno3aHd4U1NNVFRiX3FoaHQwY3h5Vkh6UmJZeDM3WVhPblFNaVhYZmxDSlQ2VGR2aUlNcG5KdFhTbmE1cDQwOHFXQVM2cURIOUhLMGMtRVktcUM1Uk4tSmNB?oc=5","date":"2026-02-06","type":"pipeline","source":"TradingView","summary":"GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share - TradingView","headline":"GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOZThxQ3dkLXp0dkU2blM0RlM3TzZVZ3NZSWFiQVAxYURlb0ZRLUtlQ1ZyWUJjN3ZSb29PeTBrNFBnUm5iZ09tbG54d0tkb1I4TzBQOGJvVlhMeHRleHU0dDBqWUlwdTgzemw0c0hCemppZDFHejlFNUxXYXRFU1ltOXd5Ulk5MzZ6d0ZrSHViSG9JTE0yNnpFWk43dVRHeDDSAVZBVV95cUxNdHJZU0pFM3Z0SllJMnVOT1l2SzhsVDB0NXhsQnhsNFl5VngtdTBBN0FpV3lic19GbS01YXJqQ2loMU5UREt0WmJreEFrV2NBRkdiUnllQQ?oc=5","date":"2025-12-02","type":"pipeline","source":"Law360","summary":"Squires Institutes First PTAB Challenges Since Taking Over - Law360","headline":"Squires Institutes First PTAB Challenges Since Taking Over - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxONDFoV2F0QVBtY1g0NGRrUHQwblh1VnJuS1FDcGl6R2RZc1pyLTJxelNzMzlyU1Z3TzdlLWtLb3VyOGRNRGliZW51ak5oOWk4OFpBSHpBdTFOQ1RiNmhTUHZoZG95ekVfR3hCSVUzeVVWWGUyVDl3aHdyVUpPVUlrd3Vjb24?oc=5","date":"2025-09-22","type":"regulatory","source":"Yahoo Finance","summary":"Ascletis Pharma trial shows drug candidate ASC47 boosts weight loss effect of semaglutide - Yahoo Finance","headline":"Ascletis Pharma trial shows drug candidate ASC47 boosts weight loss effect of semaglutide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQemkyUWtFVmN1bDQ5YU1CbVlmTVdSVnhxUGlFaTlVMkNZVkFRTHo3OU5PNXBwWWJPMVRRSjh0dDFFd1FKMUpULXozN1IzMnBNRnlEY3dSalBCWlJIdWpidVVVMFVtb1BJc19OSFg2Z3M0RDVjVFhrM1M3eUdkZVNYVmFhR3ZKM2NjYnVFZTlVQ0dtZmZybmtNMkxmN0FzXzljZXBaWEFKUzktX1dhcEJQbHRsWHQ0a3hrY19ranBlZTNrZF9Z?oc=5","date":"2025-08-19","type":"deal","source":"Citeline News & Insights","summary":"China-Originated Assets Lead Global GLP-1 Deals - Citeline News & Insights","headline":"China-Originated Assets Lead Global GLP-1 Deals - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1SZkk2a2ZSRlRPdlBlZTNPXzJUcUdCUlQyNVZ1dFdrMGZmSllQYVczVjB2dlFKTHgwZzZiNGlTNzdrNndweFU4b2VSUDlvMFQzT004?oc=5","date":"2025-07-17","type":"pipeline","source":"36 Kr","summary":"Chinese Innovative Drugs \"Selling Like Hotcakes\" Overseas! Hong Kong Stocks Soar 60%: Bubble or Starting Point? - 36 Kr","headline":"Chinese Innovative Drugs \"Selling Like Hotcakes\" Overseas! Hong Kong Stocks Soar 60%: Bubble or Starting Point? - 36 Kr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOeGNjZnQzQlJ4VTQwbHl1aFdwb0R1VW9WSFJ0OEZyYUJjclFXd2UwYkIwNDB5S1V6SGhmTnBsVWgycHpkRnBRcXUxaEJJM1dqRUtqS2V2TndOWUJPWkN2Rlo5cU95MEMzQnJDMkJtU0pZMDRDSG9yOTlUU2psWXdCRndaYkNkQzVmZUtfQ24xQy14ODJiQkIxQkNLb2k5U05nU0QxMDVnNzNQdG5rdmNrWG1Xajc?oc=5","date":"2025-06-04","type":"trial","source":"Fierce Biotech","summary":"Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators - Fierce Biotech","headline":"Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPVklLclludjRkWW5HbTFVRktrUVN0d21PRlB4SG1xR0FkaEE5UWl4SzZOSnZuRDF5TE9oWXJMNkNlVlhsd3JQck9iZzR6b3FIV2NpSDFrMjN3bG90bVVwTkNEQzdwTjdYYUJDWVNObjR2RGJWRXBpVU1JenlqRjlqLXgxU2hkREg3SVhuVVVzNjVDay1Cb1FWb0hrcTlCQm5BSVE?oc=5","date":"2025-02-21","type":"regulatory","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod - Fierce Pharma","headline":"Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTzlCQldBRFNQc3d5TDVKeEdMZkRpN1ZfMlhuVVYwNm8wN1VWdEhaM01PYUNWelphRFc4MFc0YUFOVUVZWC1Kb2Q2R2ZqU3EwcGNaTGhTSGo5MDNsUjJBTzJIQURCNGwtYXpWR1R0Z1EweDl0VElpUEhnVlpCTTRKQ0dpZ2hWa3RucHMwRGJPRG5JWHVhbXBRSFlOTzlZdzVETGI0b0d2WHEzQQ?oc=5","date":"2025-02-19","type":"pipeline","source":"Drug Topics","summary":"GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity - Drug Topics","headline":"GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPaG50UWdteEdnT3hxXzNWWUdJYXVKNGpSNGV6bzdLd1FtSW9VM19qOGhYWTA3UGk5cW1hNERFTDNsLTF3ODNjeVh1NC1KYjkzS1ZNcmt5czdQOFJoVXlINDhka0lpTlN5YXI4ZTJ4TjdvQVJSSXJpQlpSSDEzUzdJSWRfZ2VoeDZiN2N0RTdBdjJWMU5Yd3gtcnJEZjZ5Y29RWktF?oc=5","date":"2024-09-27","type":"earnings","source":"thebambooworks.com","summary":"Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs - thebambooworks.com","headline":"Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNdlR2cE8yc0t2aWZ2bGV0LTYtc3FXZVlVX1lieWstNUNiN0hfR211ZnE5aUExenNqTjJzNW1vQk5DNVByTVBCZ2stRGlHTEE2YzNpbUJ4ZlB6SmRIMDREdlJUSU9VQkFnekQ5TGNlWGNNNC14amRZbEZxNkhxdHVxc1RLeFBDRDFjbEduT1BKenM?oc=5","date":"2022-12-30","type":"pipeline","source":"Fortune","summary":"Overwhelmed by a massive outbreak, China authorizes emergency use of Merck COVID pill Lagevrio - Fortune","headline":"Overwhelmed by a massive outbreak, China authorizes emergency use of Merck COVID pill Lagevrio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE55QTN6RzBMLUdEY21idFVNMGZiSmZnT0hiSnJ3UnVhNVppc3NsaVdwODdRN2lXTENZek8xOC1yaEhhRUMyaTBMMXFlYUhIai0tdmpRSHNISzE0cDhtREdBV2ktTEhSY0xpSnRV?oc=5","date":"2022-12-29","type":"pipeline","source":"Reuters","summary":"Ascletis BioScience Co., Ltd. - Reuters","headline":"Ascletis BioScience Co., Ltd.","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}